Fiscal year 2024 generic drug user fee calculations will incorporate a new workload-based model, but not account for all of the categories initially expected.
The US Food and Drug Administration committed to incorporating a capacity planning adjustment into GDUFA III fee calculations as part of the 2022 program reauthorization. Inspections are supposed to be...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?